Abstract
Sustained adherence and persistence with prescription medications is considered essential to achieve maximal treatment benefit for patients with major chronic non-communicable diseases such as hyperlipidemia and lipid-associated cardiovascular disease. It is widely documented, however, that a large percentage of patients with these conditions have poor longer-term compliance with their treatments. The population of Russia is affected by poor compliance in the same ways as populations elsewhere and continues to have high rates of cardiovascular disease.
Hypertriglyceridemia is suspected of contributing to residual cardiovascular risk in patients whose low-density lipoprotein cholesterol (LDL-C) is well controlled. A preparation of highly purified omega-3 polyunsaturated fatty acids (EPA/DHA=1.2/1-90%, marketed as OMACOR), is indicated for the control of high triglyceride levels and also for secondary prevention of myocardial infarction (MI).
DIAPAsON is a prospective observational program designed to evaluate the impact of digital technologies on patient compliance and adherence in a large sample of patients whose treatment scheme includes EPA/DHA=1.2/1-90%. A bespoke electronic data capture system has been developed for this purpose that enables information obtained during clinic visits to be supplemented by remote patient self-reporting. Other objectives of the program include raising patients’ awareness about their condition via educational materials available in patient personal accounts in the electronic system.
This report outlines the rationale and methodology of DIAPAsOn and the primary demographics of the study population.
Competing Interest Statement
GPA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. GPA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier. AGA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. AGA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier. FTA does not have any conflicts of interest. TVF does not have any conflicts of interest.
Clinical Trial
NCT03415152
Funding Statement
The study is supported by Abbott.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Interuniversity Ethics Committee, Moscow, Russian Federation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable to this submission.
